1. Home
  2. REBN vs EVAX Comparison

REBN vs EVAX Comparison

Compare REBN & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Reborn Coffee Inc.

REBN

Reborn Coffee Inc.

N/A

Current Price

$1.98

Market Cap

12.3M

ML Signal

N/A

EVAX

Evaxion Biotech

N/A

Current Price

$3.80

Market Cap

31.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
REBN
EVAX
Founded
2015
2008
Country
United States
Denmark
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.3M
31.9M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
REBN
EVAX
Price
$1.98
$3.80
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$11.67
AVG Volume (30 Days)
53.1K
32.1K
Earning Date
03-27-2026
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,928,533.00
N/A
Revenue This Year
$335.98
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.36
$1.20
52 Week High
$4.29
$12.15

Technical Indicators

Market Signals
Indicator
REBN
EVAX
Relative Strength Index (RSI) 55.41 49.34
Support Level $1.59 $2.45
Resistance Level $1.98 $4.64
Average True Range (ATR) 0.11 0.40
MACD 0.01 0.04
Stochastic Oscillator 64.29 38.48

Price Performance

Historical Comparison
REBN
EVAX

About REBN Reborn Coffee Inc.

Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.

About EVAX Evaxion Biotech

Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.

Share on Social Networks: